For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231109:nRSI9734Sa&default-theme=true
RNS Number : 9734S IQ-AI Limited 09 November 2023
IQ-AI Ltd
("IQ-AI" or the "Company")
Director Dealing and Conversion of Convertible Loan Notes
IQ-AI Ltd has received a conversion notice from Trevor Brown, the CEO of
IQ-AI, converting £100,000 convertible loan notes and associated interest,
issued on 29 May 2019, at a price of 1.5 pence, into 8,446,393 Ordinary Shares
("CLN Shares").
Following the above transactions, Trevor Brown will hold 40,649,850 Ordinary
Shares, representing approximately 21.32 per cent. of the Company's enlarged
issued ordinary share capital.
An application will be made for 8,446,393 CLN Shares to be admitted to the
Official List of the UK Listing Authority by way of a Standard Listing
("Admission") and it is expected that Admission will become effective and that
dealing in the CLN Shares will commence on or around 8am on 15 November 2023.
The CLN Shares will rank pari passu with the existing ordinary shares of the
Company.
Following Admission, the Company will have 190,671,542 ordinary shares of
0.01p each in issue, none of which are held in treasury. Therefore, the total
number of voting rights in the Company will be 190,671,542.
The above figure of 190,671,542 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure and Transparency
Rules.
--ENDS-
The Directors of the Company accept responsibility for the contents of this
announcement.
For further information, please contact:
IQ-AI Ltd
Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
About Imaging Biometrics® LLC: IB is a wholly owned subsidiary of IQ-AI
Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms
and therapeutics that transform how clinicians diagnose and treat patients
more efficiently and effectively. For more information about Imaging
Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on Twitter, @IQAI_IB.
PDMR DEALINGS
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Trevor Brown
2 Reason for the notification
a) Position/status CEO
b) Initial notification /Amendment
Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name IQ-AI Ltd
b) LEI 213800SPW48XRJS2QH57
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of £0.01 each
Identification code
ISIN: JE00BD4H0R42
b) Nature of the transaction Conversion of convertible loan notes
c) Price(s) and volume(s) Exercise price of each convertible loan note :1.5p
Volume: 8,446,393
d) Aggregated information
- Aggregated volume
- Price
e) Date of the transaction 9 November 2023
f) Place of the transaction Main Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFSWFFUEDSEDF